India’s Sun Pharmaceutical Industries has entered into an exclusive licensing and supply agreement with Rockwell Medical to sell the U.S. company’s iron replacement drug in India.
Under the agreement, the India-listed company will have exclusive development and commercial rights for Triferic, subject to approval in India, Sun Pharmaceutical said in a filing to the Bombay Stock Exchange on Wednesday.
Financial terms of the agreement weren’t disclosed.
Rockwell will be eligible for upfront and milestone payments as well as royalty on net sales under to the licensing agreement, according to the statement.
Triferic is a iron replacement and haemoglobin maintenance drug used for treating anaemia in hemodialysis patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.